Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP). While the ...

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its price objective boosted by equities researchers at Piper Sandler from $4.00 to $6.00 in a research report issued on Friday,Benzinga reports.

恩那度司他（Enarodustat）是一种缺氧诱导因子脯氨酰羟化酶抑制剂（hypoxia-inducible factor-prolyl hydroxylase inhibitor）。研究对国产恩那度司他（SAL-0951）的药代动力学、药效学以及安全性进行了评估，并分析了种族因素对其的影响。在这项 I 期研究中，健康的中国参与 ...

After hours: March 14 at 7:58:30 p.m. EDT Loading Chart for FGEN ...

As of 3:24:03 pm GMT-4. Market open. Loading Chart for AKBA ...